EndoShunt

Executive Summary

EndoShunt is developing a minimally invasive, targeted hemorrhage control device designed to provide trauma surgeons with critical time during exsanguinating injuries. The current standard of care often fails to prevent death from hemorrhage due to the time required to access the injury site. EndoShunt's innovative shunt technology aims to rapidly control bleeding, potentially improving survival rates in both civilian and military trauma settings. The company, founded in 2019 and based in San Francisco, is addressing a large market opportunity in trauma care. While still in early stages, EndoShunt's device could become a game-changer in emergency medicine, offering a solution that is less invasive and faster than current methods. The company's success hinges on clinical validation, regulatory approval, and adoption by trauma centers.

Upcoming Catalysts (preview)

• Q4 2026First-in-human clinical trial results60% success
• Q2 2027FDA Breakthrough Device Designation or 510(k) submission70% success
• Q3 2026Strategic partnership with a major trauma device distributor50% success